Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Alpha Tau Medical Ltd. DRTSW NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • IL • USD

SharesGrow Score
40/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Alpha Tau Medical Ltd. (DRTSW) is a Biotechnology company in the Healthcare sector, currently trading at $0.94. It has a SharesGrow Score of 38/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Valuation: DRTSW trades at a trailing Price-to-Earnings (P/E) of -14.6 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.88.

Net income is $43M (loss), growing at -9.8%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $14M against $77M equity (Debt-to-Equity (D/E) ratio 0.18, conservative). Current ratio is 7.45 (strong liquidity). Debt-to-assets is 12.9%. Total assets: $107M.

SharesGrow 7-Criteria breakdown: Value 90/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 28/100 (Fail), Future ?/100 (Fail), Income ?/100 (Fail).

DRTSW SharesGrow Score Overview

50/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 90/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — DRTSW

✓
VALUE Pass
90/100
DRTSW trades at a trailing Price-to-Earnings (P/E) of -14.6 (S&P 500 average ~25). Forward PEG 0.88 — Peter Lynch undervalued (≤1.0). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
DRTSW: +0%/yr revenue is, -9.8%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet DRTSW: Debt-to-Equity (D/E) ratio 0.18 (conservative), Current ratio is 7.45 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
DRTSW: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.3251-0.9601
Volume17.86K
Avg Volume (30D)21.51K
Market Cap$82.72M
Beta (1Y)1.05
Share Statistics
EPS (TTM)-0.53
Shares Outstanding$80.58M
Employees125
CEOUzi Sofer
Financial Highlights & Ratios
Gross Profit$-1.23M
EBITDA$-41.06M
Net Income$-42.63M
Operating Income$-42.29M
Total Cash$76.9M
Total Debt$13.73M
Net Debt$-2.25M
Total Assets$106.58M
Price / Earnings (P/E)-1.8
Analyst Forecast
Company Info
CountryIL
ExchangeNASDAQ Global Market
CurrencyUSD
ISINIL0011839466

Price Chart

Track all markets on TradingView
DRTSW
Alpha Tau Medical Ltd. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
0.33 52WK RANGE 0.96

People Also View

EQRXW
EQRXW
EQRx, Inc.
$0.05
+0.00%
 DRTS
DRTS
Alpha Tau Medical Ltd.
$7.83
+2.49%
 REVBW
REVBW
Revelation Biosciences, Inc.
$0.01
-1.10%
 EFTRW
EFTRW
eFFECTOR Therapeutics, Inc.
$0.00
0.00%
 GRNAW
GRNAW
GreenLight Biosciences Holdings
$0.02
+8.91%
 LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message